BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37257767)

  • 1. Casein kinase 1 controls the shuttling of epidermal growth factor receptor and estrogen receptor in endometrial carcinoma induced by breast cancer hormonal therapy: Relevance of GPER1/Src.
    Hoang LN; Lee SJ
    Cell Signal; 2023 Aug; 108():110733. PubMed ID: 37257767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
    Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M
    Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
    Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
    Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estradiol and tamoxifen induce cell migration through GPR30 and activation of focal adhesion kinase (FAK) in endometrial cancers with low or without nuclear estrogen receptor α (ERα).
    Tsai CL; Wu HM; Lin CY; Lin YJ; Chao A; Wang TH; Hsueh S; Lai CH; Wang HS
    PLoS One; 2013; 8(9):e72999. PubMed ID: 24039841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
    Shah YM; Rowan BG
    Mol Endocrinol; 2005 Mar; 19(3):732-48. PubMed ID: 15528270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells.
    Sakamoto T; Eguchi H; Omoto Y; Ayabe T; Mori H; Hayashi S
    Mol Cell Endocrinol; 2002 Jun; 192(1-2):93-104. PubMed ID: 12088871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
    Yang F; Xie HY; Yang LF; Zhang L; Zhang FL; Liu HY; Li DQ; Shao ZM
    Autophagy; 2020 Jun; 16(6):1061-1076. PubMed ID: 32401166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
    Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPER mediates the Egr-1 expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells.
    Vivacqua A; Romeo E; De Marco P; De Francesco EM; Abonante S; Maggiolini M
    Breast Cancer Res Treat; 2012 Jun; 133(3):1025-35. PubMed ID: 22147081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer.
    Jeong Y; Bae SY; You D; Jung SP; Choi HJ; Kim I; Lee SK; Yu J; Kim SW; Lee JE; Kim S; Nam SJ
    Cell Physiol Biochem; 2019; 53(5):805-819. PubMed ID: 31670920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
    Fan P; Wang J; Santen RJ; Yue W
    Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells.
    Block M; Fister S; Emons G; Seeber S; Gründker C; Günthert AR
    Anticancer Res; 2010 Jun; 30(6):2025-31. PubMed ID: 20651347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPER1-mediated IGFBP-1 induction modulates IGF-1-dependent signaling in tamoxifen-treated breast cancer cells.
    Vaziri-Gohar A; Houston KD
    Mol Cell Endocrinol; 2016 Feb; 422():160-171. PubMed ID: 26690777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen has a proliferative effect in endometrial carcinoma mediated via the GPER/EGFR/ERK/cyclin D1 pathway: A retrospective study and an in vitro study.
    Zhang L; Li Y; Lan L; Liu R; Wu Y; Qu Q; Wen K
    Mol Cell Endocrinol; 2016 Dec; 437():51-61. PubMed ID: 27519631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.
    Zhang N; Sun P; Xu Y; Li H; Liu H; Wang L; Cao Y; Zhou K; TinghuaiWang
    Cancer Lett; 2021 Feb; 498():54-69. PubMed ID: 33069770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-dependent GPER1 expression modulates tamoxifen-induced IGFBP-1 accumulation.
    Zheng Y; Houston KD
    J Mol Endocrinol; 2019 Aug; 63(2):103-112. PubMed ID: 31242463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context.
    Castro-Rivera E; Safe S
    J Steroid Biochem Mol Biol; 2003 Jan; 84(1):23-31. PubMed ID: 12648521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.
    Shah YM; Al-Dhaheri M; Dong Y; Ip C; Jones FE; Rowan BG
    Mol Cancer Ther; 2005 Aug; 4(8):1239-49. PubMed ID: 16093440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERα36-GPER1 Collaboration Inhibits TLR4/NFκB-Induced Pro-Inflammatory Activity in Breast Cancer Cells.
    Notas G; Panagiotopoulos A; Vamvoukaki R; Kalyvianaki K; Kiagiadaki F; Deli A; Kampa M; Castanas E
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.